In a report released today, Alex Arfaei from BMO Capital maintained a Buy rating on Bristol Myers (BMY), with a price target of $60. The company’s shares closed on Friday at $53.08.
According to TipRanks.com, Arfaei is a 5-star analyst with an average return of 8.6% and a 72.1% success rate. Arfaei covers the Healthcare sector, focusing on stocks such as Elanco Animal Health Inc, Merck & Company, and Eli Lilly & Co.
The word on The Street in general, suggests a Hold analyst consensus rating for Bristol Myers with a $59.50 average price target, implying a 12.1% upside from current levels. In a report issued on November 27, William Blair also maintained a Buy rating on the stock.
.
See today’s analyst top recommended stocks >>
Based on Bristol Myers’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $5.69 billion and net profit of $1.9 billion. In comparison, last year the company earned revenue of $5.25 billion and had a net profit of $845 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It includes chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.
